请使用支持JavaScript的浏览器!
主营:分子类化合物
℡ 4000-520-616
℡ 4000-520-616
Qiagen/Rapid Capture System/6000-3101
产品编号:6000-3101
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: Qiagen
公      司:Qiagen
公司分类:
Qiagen/Rapid Capture System/6000-3101
商品介绍

Rapid Capture System

Product picture
For high-throughput Hybrid Capture 2 (HC2) assays
  • Streamlines digene HC2 High-Risk HPV and HC2 CT/GC DNA tests
  • Significant increase in labor savings
  • Decreases turn-around time for delivering results to physicians
  • Enables the laboratory to increase testing capacity
The Rapid Capture System is a semi-automated pipetting and microplate handling system for high-volume sample-throughput testing. This system handles up to 352 specimens and 1 to 4 platesin a single8 hour shift. The Rapid Capture System fits on a standard bench top andis compatible withsoftware that providesLIS interface connectivity.
  • Buy Products
  • Product Details
  • Service Plans
  • Product Resources

Buy Products

Cat No./ID:6000-3101
Rapid Capture System
Inquire
Rapid Capture System for high-volume sample throughput.
Cat No./ID:9001931
HC2 RCS Complete Instrument Package
Inquire
Complete system for high-volume sample throughput, including: Rapid Capture System, Vortexer, Racks, Microplate Luminometer, and validated PC System Package
Cat No./ID:9001932
HC2 RCS Upgrade Instrument Package
Inquire
Upgrade package for existing HC2 customers, including: installation of Rapid Capture System and HC2 System on existing validated hardware

The Rapid Capture System is intended to be used only in combination with QIAGEN Kits indicated for use with Rapid Capture System for applications described in the respective QIAGEN Kit handbooks.

Product Details

9
In vitro diagnostic device.
Performance

The Rapid Capture System (RCS) is FDA-approved (see IVD mark) for use with the digene HC2 High-Risk HPV DNA Test, digene HC2 CT/GC DNA Test, digene HC2 CT-ID DNA Test, and the digene HC2 GC-ID DNA Test. The system processes cervical samples collected in Specimen Transport Medium (STM), which is part of the digene Cervical Sampler. Other digene tests or sample types may be available for use on the RCS, depending on country regulations.

Onboard reagent stability 

The RCS provides reagent stability of 16 hours for those reagents most likely to be subject to extended onboard placement — Probe Mix, Detection Reagent 1, Detection Reagent 2, and the Capture Plates (see table).

Agreement of calibrator and control results of fresh vs. aged reagents
Overall agreementPositive agreementNegative agreementR2SlopeInterceptKappa
100% 96/97 (97.97–100)100% 64/64 (97.97–100)100% 32/32 (97.97–100)0.99360.970.471.0
The assay performance of reagents was evaluated using freshly prepared reagents vs. reagents that were aged onboard the Rapid Capture System platform at room temperature for a period of 16 hours to simulate 2 work shifts in a laboratory setting. Simulated clinical specimens were tested using 2 Rapid Capture Systems each on 2 days (RCS 1: aged reagents on day 1 and fresh reagents on day 2; RCS 2: fresh reagents on day 1 and aged reagents on day 2). Results were comparable for fresh vs. aged reagents (CI: 95%), indicating that reagents are sufficiently stable when placed onboard the instrument for a period of up to 16 hours.
Agreement of Rapid Capture System vs. manual HPV test methods 

The Rapid Capture System HPV application results show agreement with the manual method in clinical specimens. Statistical agreement was shown for cervical specimens collected in ThinPrep PreservCyt solution and STM (see tables).

RCS vs. manual HPV test method: STM patient specimen data (n=1001)
Cyt. class.HPV preval. %Overall + agreement % (n/N)Strong + region (>2.5)Overall – agreement % (n/N)Strong – region (<0.8)
WNL <30 years21%99.3% (139/140) 96.1, 10099.1% (112/113) 95.2, 10099.3% (538/542) 98.1, 99.8100% (531/531) 99.3, 100
WNL 30+ years15%92.0% (23/25)96.1, 10093.8% (15/16)69.8, 99.8100% (143/143) 97.5, 100100% (142/142) 97.4, 100
ASC-US65%98.1% (51/52)89.7, 100100% (47/47)92.4, 10096.4% (27/28) 81.7, 99.9100% (26/26) 86.8, 100
LSIL+96%100% (65/65) 94.5, 100100%(62/62) 94.2, 10066.7% (2/3) 9.4, 99.266.7% (2/3) 9.4, 99.2
Other33%100% (1/1)    2.5, 100100% (1/1)    2.5, 100100% (2/2)   15.8, 100100% (2/2)   15.8, 100
All STM28%98.6% (279/283) 96.4, 99.699.2% (237/239) 97.0, 99.999.2% (712/718) 98.2, 99.799.9% (703/704) 99.2, 100
Clinical results using the Rapid Capture System were compared with results obtained using the manual method in a multicenter study (N=2270 patients). Patient specimens were collected from 5 collection sites and testing was performed at 3 external sites. The data set consisted of cervical specimens collected in ThinPrep PreservCyt Solution (1269) and Specimen Transport Medium (1001). Confidence interval=95%. LSIL+: low-grade squamous intraepithelial lesion or greater; +: positive; –: negative; ASC-US: atypical squamous cells of undetermined significance; STM: Specimen Transport Medium; WNL: within normal limits.

 

RCS vs. manual HPV test method ThinPrep PreservCyt clinical specimen data (n=1269)
Cyt. classHPV preval. %Overall + agreement %  (n/N)Strong + region (>2.5)Overall agreement % (n/N)Strong – region (<0.8)
WNL <30 years20%96.2% (75/78) 89.2, 99.2100% (64/64) 94.4, 10098.4% (301/306) 96.2, 99.599.0% (293/296) 97.1, 99.8
WNL 30+ years8%88.7 (47/53) 77.0, 95.792.1% (35/38) 78.6, 98.399.1% (578/583) 98.0, 99.799.5% (571/574) 98.5, 99.9
ASC-US36%100% (48/48) 92.6, 100100% (46/46) 92.3, 10096.6% (84/87) 90.3, 99.396.5% (83/86) 90.1, 99.3
LSIL+77%100% (64/64) 94.4, 100100% (62/62) 94.2, 10089.5% (17/19) 66.9, 98.788.9% (16/18) 65.3, 98.6
Other11%100% (3/3) 29.2, 100100% (3/3) 29.2, 100100% (24/24) 85.6, 100100% (24/24) 85.8, 100
All PreservCyt Clinical20%96.4% (238/247) 93.2, 98.398.6% (211/214) 96.0, 99.798.5% (1007/1022) 97.6, 99.298.9% (990/1001) 98.0, 99.4
Clinical results using the Rapid Capture System were compared with those obtained with the manual method in a multicenter study (N=2270 patients). Patient specimens were collected from 5 collection sites, with testing performed at 3 external sites. The data set consisted of cervical specimens collected in ThinPrep PreservCyt Solution (1269) and Specimen Transport Medium (1001). In the results for the ThinPrep PreservCyt Solution, cytology data was unavailable from 4 patients. Confidence interval = 95%. LSIL+: low-grade squamous intraepithelial lesion or greater; +: positive; : negative; ASC-US: atypical squamous cells of undetermined significance; WNL: within normal limits.
Principle

The Rapid Capture System reduces repetitive manual steps, with technology that performs semi-automated assays. The system is designed to work with the Hybrid Capture 2 screening technology, and it is the only high-throughput system for testing cervical samples with the FDA-approved digene HC2 High-Risk HPV DNA Test. The Rapid Capture system provides the flexibility of multiple software scripts, allowing laboratories to adjust their schedules to improve workflow.

Specimen contamination or carryover of residual alkaline phophotase is minimized through the use of disposable pipette tips for reagent and specimen aspiration. The system automates sample transfers (from sample tubes to hybridization plate, then from hybridization plate to Capture Plate), plate handline, precision reagent pipetting with liquid level-sensing tips, incubation at ambient and 65°C temperatures, and washing.

Procedure
Multiple assays for flexible workflows

The Rapid Capture System (RCS) accommodates multiple assays or sample types during a single run — enabling scheduling flexibility. For instance, when running a single run of the digene HC2 High-Risk HPV DNA Test on the RCS, separate plates can handle both liquid based cytology (LBC) samples and digene cervical samples.

The Rapid Capture System can be used with the digene HC2 High-Risk HPV DNA Test, digene HC2 CT-ID DNA test, and digene HC2 GC-ID DNA Test. Depending on the test, the specimens can be collected using the digene Cervical Sampler, Specimen Transport Medium (STM), digene Female Swab Specimen Collection Kit, and PreservCyt solution.

High-throughput design for optimized workflow

The Rapid Capture System performs up to 352 tests/8 hours, automating 6 procedural steps of the manual method:

  • Specimen pipetting
  • Regent dispensing
  • Microplate handling
  • Microplate mixing
  • Microplate incubation
  • Microplate washing

User intervention is limited to specimen preparation, loading of specimen racks onto the deck, deck setup, chemiluminescent signal detection, and result reporting. Denaturation of the specimens in preparation for testing with the digene HC2 DNA Tests is performed independently of the Rapid Capture System. In addition, amplified chemiluminescent signal detection and result reporting are performed using the offline DML 2000/3000 Instrument and using the digene Hybrid Capture System Version 2 (DHCS v.2) Software.

The Rapid Capture System is intended to be used only in combination with QIAGEN kits indicated for use with the Rapid Capture System for applications described in the kit handbooks.

Applications

A range of digene HC2 DNA Tests enable high-throughput detection of pathogens using the Rapid Capture System. Using kits for Hybrid Capture applications, the Rapid Capture System automates detection of:

  • High-risk human papillomavirus (HPV) infection
  • Chlamydia trachomatis (CT) infections
  • Neisseria gonorrhoeae (GC) infections
Software

The HC2 System Software reports qualitative assay results with a user-friendly interface. Software supports customizable report formats — sorted by plate or specimen, with summary or detailed outputs. All results are tracked by the user ID for auditing and QA. The Rapid Capture System ScriptSelect Software allows users to choose the appropriate protocol and number of tests being run.

The HC2 System Software is compatible with multiple types of bar codes, which saves time and reduces manual entry errors. The software fully interfaces with Laboratory Information Systems (LIS), through which designated users can send patient and QC data to the laboratory network.

Service Plans

Cat No./ID:9243231
RCS, Full Agreement
Inquire

On-site QIAsymphony RGQ instrument repair, including travel, labor and parts, for a period of one year. Response time of two business days. Includes one Preventive Maintenance or Inspection Service during the Full Agreement period.

Cat No./ID:9243550A
RCS, Preventive Subscription
Inquire

One on-site Preventive Maintenance or Inspection Service visit for the Rapid Capture System, including travel, labor and parts. Includes a 10% discount on repair services during the Preventive Subscription period.

The Rapid Capture System is intended to be used only in combination with QIAGEN Kits indicated for use with Rapid Capture System for applications described in the respective QIAGEN Kit handbooks.

Product Resources

fragment fix placeholder
品牌介绍

QIAGEN是一家专业化致力于生物分子样品制备解决方案的跨国经营企业,总部位于德国。1984年,QIAGEN在德国成立,1996年在美国纽约纳斯达克上市。

QIAGEN拥有超过1000项专利和认可证明,在18个国家设立了分公司,代理商服务国超过40个,在全球有超过400000的用户。QIAGEN提供的产品超过500类,包括各种试剂,耗材和自动化纯化工作站。这些产品用于样品采集,稳定,核酸或蛋白的分离,纯化和检测中,不仅广泛的应用于科研领域的各个方面,在生物技术,制药,法医研究,食品安全检测,畜牧业和分子诊断领域也得到了广泛的应用。QIAGEN产品的卓越品质和在应用中的出色表现使得其成为样品处理中标准的代名词。


自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔